PFA

Revenue growth above 20%Net loss reportedEBITDA margin compressionNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.3%Reaction day

₹0.61

prior close

₹0.61

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.4%+3.6% vs market

Pharmaceuticals & Biotechnology peers, median of 164sector · industry level-0.2%+3.4% vs sector

On the reaction day the stock moved 3.6 pts more than Nifty Microcap 250 and 3.4 pts more than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

-1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.3-0.4+3.6-0.2+3.4

Next day

-1.6-1.7+0.1-0.9-0.7

-1.6-1.3-0.4-0.2-1.4

+0.0-0.7+0.7+0.2-0.2

-1.6+0.4-2.0+0.7-2.4

-1.6+0.5-2.1+0.2-1.8

-1.6+2.8-4.5+1.0-2.6

15d

-1.6+1.2-2.8-0.2-1.4

+0.0+5.3-5.3+1.5-1.5

-6.6+9.9-16.5+7.7-14.3

-16.4+13.1-29.5+8.1-24.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals & Biotechnology peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shree Ganesh Biotech reported standalone revenue of Rs. 2,295.76 lakhs for FY26, up from Rs. 497.05 lakhs in FY25—a massive 362% increase. However, the company posted a net profit after tax of Rs. 27.84 lakhs, down from Rs. 37.76 lakhs the prior year (26% decline). Total expenses of Rs. 2,401.16 lakhs nearly matched total income of Rs. 2,439.85 lakhs, resulting in tight operating margins. The balance sheet shows Rs. 4,274.88 lakhs in long-term loans against minimal fixed assets of Rs. 0.13 lakhs, suggesting the company operates primarily as a financial services/loan business rather than a typical biotech manufacturer. The statutory auditor issued an Unmodified Opinion confirming clean financials. Cash flow from operating activities was negative at Rs. 819.56 lakhs.

Likely market impact

The stock may see mixed reactions—the top-line growth is impressive but shrinking margins and declining PAT suggest underlying profitability issues. The unusual balance sheet composition (heavy loans, minimal assets) warrants caution for investors seeking a genuine biotech play.